XM无法为美国居民提供服务。
R
R

Roche


市场新闻

Roche Holding Publishes Data Regarding Evrysdi Efficacy

BRIEF-Roche Holding Publishes Data Regarding Evrysdi Efficacy Oct 14 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE DATA CONFIRM EVRYSDI EFFICACY AND SAFETY IN CHILDREN FIRST TREATED PRE-SYMPTOMATICALLY BEFORE 6 WEEKS OF AGE, WITH MOST ACHIEVING MOTOR MILESTONES SIMILAR TO CHILDREN WITHOUT SMA Source text for Eikon: ID:nBw92GX3Ja Further company cov
R

Roche Receives FDA Approval For Itovebi

BRIEF-Roche Receives FDA Approval For Itovebi Oct 11 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES ROCHE’S ITOVEBI, A TARGETED TREATMENT FOR ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH A PIK3CA MUTATION ROCHE HOLDING AG - ITOVEBI REGIMEN DOUBLES PROGRESSION-FREE SURVIVAL IN PHASE III STUDY ROCHE HOLDING AG - ITOVEBI R
R

FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer

BRIEF-FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer Oct 10 (Reuters) - FDA: FDA APPROVES INAVOLISIB WITH PALBOCICLIB AND FULVESTRANT FOR ENDOCRINE-RESISTANT, PIK3CA-MUTATED, HR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER FDA: APPROVED FOUNDATIONONE
R

Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study

BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study ** Shares of drug developer Tempest Therapeutics TPST.O up 19.21% at $1.60 premarket ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's ROG.S Tecentriq and bevacizumab, for the treatment of me
R

Roche Obtains CE Certification For Companion Diagnostic

BRIEF-Roche Obtains CE Certification For Companion Diagnostic Oct 10 (Reuters) - ROCHE HOLDING AG ROG.S : OBTAINS CE CERTIFICATION FOR THE FIRST COMPANION DIAGNOSTIC TO IDENTIFY PATIENTS WITH GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER ELIGIBLE FOR TARGETED TREATMENT WITH VYLOY Source text for Eikon: ID:nGNE1TDGf7 Further company coverage: ROG.S (
R

Roche CEO: breast cancer pill could enter $12 bln market if trials succeed

UPDATE 1-Roche CEO: breast cancer pill could enter $12 bln market if trials succeed Adds background from paragraph 2 By Ludwig Burger MANNHEIM, Germany, Oct 9 (Reuters) - Roche's ROG.S experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion) a year if it clears two key trials on early treatment of the disease, the Swiss drugmaker's CEO said.
A
R
S

Roche CEO: breast cancer pill could be in 10 bln CHF market if trials succeed

Roche CEO: breast cancer pill could be in 10 bln CHF market if trials succeed FRANKFURT, Oct 9 (Reuters) - Roche's ROG.S CEO said on Wednesday that the Swiss drugmaker's oral drug candidate for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($11.66 billion) annually if it succeeds in two key trials on early treatment of the disease.
R

Scholar Rock shares jump 300% after rare disease drug scores trial win

UPDATE 3-Scholar Rock shares jump 300% after rare disease drug scores trial win Adds analyst comments in paragraphs 6 and 7, similar drugs in paragraphs 5 and 8, updates shares By Christy Santhosh Oct 7 (Reuters) - Scholar Rock's SRRK.O experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early trading.
B
N
R

WHO approves first mpox diagnostic test for emergency use

UPDATE 4-WHO approves first mpox diagnostic test for emergency use Updates Oct. 3 story to add company statement in paragraph 4 Oct 3 (Reuters) - The World Health Organization authorized Abbott Laboratories' ABT.N mpox diagnostic test for emergency use on Thursday, the first such approval in the agency's effort to bolster testing capabilities in countries facing outbreaks of the disease.
A
R
L

Financial Times - Oct 1

PRESS DIGEST- Financial Times - Oct 1 Oct 1 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Simon Case steps down as UK cabinet secretary - EY picks Anna Anthony as UK boss after three-way race - Roche plans to launch drugs and slash development costs - LVMH sells Off-White streetwear brand founded by Virgil Abloh - Qatar Airways agrees to buy 25% stake in Virgin Australia Overview Sim
L
R

Roche targets more than $3 billion in annual obesity sales

UPDATE 1-Roche targets more than $3 billion in annual obesity sales Releads By Ludwig Burger FRANKFURT, Sept 30 (Reuters) - Roche ROG.S said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billion) in annual sales . In a presentation to investors, the Swiss drugmaker said the revenue projection applies on aggregate to weekly injection CT-388 - which is similar t
R

Roche aims to slash drug development time and costs by 2030

Roche aims to slash drug development time and costs by 2030 FRANKFURT, Sept 30 (Reuters) - Swiss drugmaker Roche ROG.S said on Monday it aims to slash the development costs of drugs it brings to market and speed up their development time by 2030. Average development costs of a drug that is launched should decline by 20% and the time from early drug discovery to the end of Phase 3 testing on humans would be cut by 40%, according to presentation slides posted on the company's website.
R

Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis

BRIEF-Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis Sept 26 (Reuters) - Roche Holding AG ROG.S : POSITIVE PHASE III RESULTS FOR GENENTECH’S GAZYVA SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS Source text for Eikon: ID:nBw2HSqmRa Further co
R

Vontobel raises Roche to 'buy' ahead of expected strategy update

BUZZ-Vontobel raises Roche to 'buy' ahead of expected strategy update ** Vontobel raises Roche ROG.S to "buy" from "hold" based on the Swiss drugmaker's planned R&D cost controls and ahead of its expected strategy update at the end of the month ** The company's Pharma Day on Sept. 30 is the key event to understanding how the new leadership will run
R

Roche Says Positive Phase III Results For Gazyva/Gazyvaro Show Superiority To Standard Therapy Alone In People With Lupus Nephritis

BRIEF-Roche Says Positive Phase III Results For Gazyva/Gazyvaro Show Superiority To Standard Therapy Alone In People With Lupus Nephritis Sept 26 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE PHASE III RESULTS FOR ROCHE’S GAZYVA/GAZYVARO SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS REGENCY STUDY MET ITS PRIMARY ENDPOI
R

ROche: WHO Endorses Dual-Stain Cytology Testing In Its Cervical Cancer Prevention Guidelines

BRIEF-ROche: WHO Endorses Dual-Stain Cytology Testing In Its Cervical Cancer Prevention Guidelines Sept 23 (Reuters) - ROCHE HOLDING AG ROG.S : WHO ENDORSES DUAL-STAIN CYTOLOGY (CINTEC PLUS) TESTING IN ITS CERVICAL CANCER PREVENTION GUIDELINES, ADVANCING PATIENT CARE AND UNDERLINING ROCHE’S ROLE IN PIONEERING CERVICAL CANCER SOLUTIONS Source text
R

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

UPDATE 1-Sanofi's tolebrutinib drug delays progressive MS by 31% in trial Adds details and background throughout By Ludwig Burger FRANKFURT, Sept 20 (Reuters) - Sanofi SASY.PA said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
N
R
S

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Swiss stocks - Factors to watch on September 19

Swiss stocks - Factors to watch on September 19 ZURICH/GDANSK, September 19 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ROCHE HOLDING AG ROG.S Roche says phase III results show Xofluza significantly reduces the transmission of influenza viruses. RICHEMONT CFR.S - 2.75 CHF/shr dividend ECONOMY Swiss August trade balance due at 0600 GMT.
A
R
R
S

Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses

BRIEF-Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses Sept 19 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE PHASE III RESULTS SHOW XOFLUZA SIGNIFICANTLY REDUCES THE TRANSMISSION OF INFLUENZA VIRUSES DATA FROM CENTERSTONE STUDY SHOWS SINGLE-DOSE XOFLUZA REDUCES TRANSMISSION OF INFLUENZA FROM AN I
R



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明